Ms. Gira Sardesai is a Chartered Accountant and Certified Public Accountant (CPA). Ms. Sardesai was earlier associated with companies like Pidilite Industries Limited, ICICI Bank, British Petroleum and Johnson & Johnson. She is a dynamic and result oriented finance professional with more than 35 years of experience across different industries and multiple geographies. She holds extensive hands-on experience in management and business leadership, with an established record of success in significa...
Novartis United States ; Healthcare professionals ; Media center ; Novartis clinical pipeline ; Other Novartis US websites
Novartis in Ireland We invite you to learn more about Novartis and our impact on patients, families and their communities. Learn More
Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS[2]; Mayzent addresses a critical unmet need for RRMS patients in transition and those with active SPMS who have transitioned · Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including impact on physical disability and cognitive decline[3] · Mayzent is approved across the MS spectrum for clin...
Multiple sclerosis (MS) ; Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis ; Fighting MS through innovation
When Microsoft released the Kinect system for playing Xbox video games about five years ago, it attracted the interest of an unlikely source: the healthcare company Novartis. For years, Novartis has been trying to find more consistent ways to quantify whether the treatments it is developing for multiple sclerosis are working, but assessing whether a patient’s symptoms are stabilizing or getting worse is complicated. That’s partly because multiple sclerosis itself is complicated: In some patients, symptoms might progress with heartbreaking s ...
About the Role ; Location: This is a UK London head office based role with hybrid working (12 days per month in the office). #LI-Hybrid · Novartis is unable to offer relocation or visa support for this role: please only apply if this location is feasible for you and you have the right to work in the UK. Major accountabilities:
absence of relapses, leading to a progressive accumulation of neurological disability9 . Approximately 85% of patients initially present with relapsing forms of MS7 . About Novartis in MS ...
The digital press release with multimedia content can be accessed here: Basel, January 20, 2020 — Novartis today announced the European Commission (EC) has approved Mayzent ® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Although every patient’s MS journey is unique, up to 80% of relapsing remitting MS (RRMS) patients will eventually transition to S...
On Thursday of last week, the US Supreme Court (SCOTUS) allowed the launch of generic versions of Novartis’s Gilenya, siding with China’s HEC Pharm Co and other pharmaceutical companies that plan to sell generics in the US. The litigation between Novartis and HEC has been ongoing since 2015 when the former sued the latter for infringing on a patent and attempting to market a generic version of the drug Gilenya. In that case, HEC claimed the Novartis patent was incomplete because it lacked pr...